10-Q: Immunic Faces Going Concern, Nasdaq Delisting Amid Losses

Immunic, Inc. reported increased net losses and a going concern warning, alongside a Nasdaq delisting notice, despite positive clinical trial updates for its lead drug candidates.

Summary

• Immunic, Inc. reported a net loss of $25.6 million for the three months ended September 30, 2025, compared to $24.4 million for the same period in 2024, and a net loss of $77.9 million for the nine months ended September 30, 2025, compared to $75.3 million for the same period in 2024.
• The company's accumulated deficit reached approximately $589.3 million as of September 30, 2025, up from $511.4 million at December 31, 2024.
• Cash and cash equivalents stood at $35.1 million as of September 30, 2025, a slight decrease from $35.7 million at December 31, 2024.
• Management has raised substantial doubt about the company's ability to continue as a going concern, stating it lacks adequate liquidity to fund operations for at least twelve months without raising additional capital.
• Immunic received a Nasdaq non-compliance notice on June 27, 2025, for its common stock trading below $1.00 per share, with a compliance deadline of December 24, 2025.
• The second and third tranches of the January 2024 private placement, which could have provided an additional $160 million, were not exercised and expired on October 31, 2025, due to unmet conditions.
• The company completed enrollment for both Phase 3 ENSURE trials of vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS), with top-line data expected by the end of 2026.
• Positive clinical data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) was presented at ECTRIMS, showing reductions in disability progression and brain volume loss.
• A new patent was allowed by the USPTO for vidofludimus calcium dose strengths in PMS, providing protection into 2041.
• IMU-856 showed a dose-dependent increase of GLP-1 in celiac disease patients and preclinical evidence of reducing body weight gain, suggesting potential for weight management.
• The company raised approximately $4.7 million net from an April 2025 common stock offering and $65 million gross from a May 2025 offering of pre-funded and common stock warrants, with potential for an additional $130 million if warrants are fully exercised.
• Total operating expenses increased to $79.9 million for the nine months ended September 30, 2025, from $72.4 million in the prior year, driven by higher R&D costs for Phase 3 trials and increased G&A expenses.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the explicit 'going concern' warning, the failure of significant capital raise tranches to close, and the Nasdaq delisting notice. While there are positive clinical trial updates and patent news, the severe financial and market standing issues overshadow these developments, indicating high risk and instability.

Positives

• Completion of enrollment for both Phase 3 ENSURE trials of vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS) is a significant step towards potential regulatory approval.
• Positive clinical data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) demonstrated reductions in 24-week confirmed disability progression, confirmed disability improvement, and annualized rate of thalamic brain volume loss, reinforcing its neuroprotective potential.
• Long-term open-label extension data from the Phase 2 EMPhASIS trial in RRMS showed robust efficacy signals and a favorable safety and tolerability profile for vidofludimus calcium over treatment durations of up to 5.5 years, with low discontinuation rates.
• Receipt of a Notice of Allowance from the USPTO for a patent protecting vidofludimus calcium's dose strengths in PMS extends intellectual property protection into 2041, with potential for further extension.
• IMU-856 demonstrated a dose-dependent increase of GLP-1 in celiac disease patients and showed preclinical effects on body weight gain and food consumption, indicating potential for weight management beyond gastrointestinal diseases.
• The company successfully raised $4.7 million net from an April 2025 offering and $65 million gross from a May 2025 offering, providing capital for ongoing operations, with a potential for an additional $130 million from warrant exercises.

Negatives

• The company reported a net loss of $25.6 million for the three months ended September 30, 2025, an increase from $24.4 million in the prior year, and a net loss of $77.9 million for the nine months ended September 30, 2025, up from $75.3 million.
• Accumulated deficit increased significantly to $589.3 million as of September 30, 2025, from $511.4 million at December 31, 2024, indicating continued operational losses.
• Cash and cash equivalents decreased slightly to $35.1 million as of September 30, 2025, from $35.7 million at December 31, 2024, despite recent capital raises.
• Net cash used in operating activities increased to $66.5 million for the nine months ended September 30, 2025, from $61.8 million in the prior year, reflecting an accelerating cash burn.
• The second and third tranches of the January 2024 private placement, which could have provided an additional $160 million in funding, were not exercised and expired on October 31, 2025, due to unmet conditions, significantly impacting expected liquidity.
• The company received a Nasdaq non-compliance notice on June 27, 2025, for its common stock trading below $1.00, with a deadline of December 24, 2025, to regain compliance, raising the risk of delisting.
• Total current liabilities increased to $30.1 million as of September 30, 2025, from $22.2 million at December 31, 2024, while total stockholders' equity decreased to $10.5 million from $18.4 million.

Risks

• The company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these financial statements without raising additional capital, which raises substantial doubt about its ability to continue as a going concern.
• Failure to obtain additional capital would have a material adverse effect on operations and clinical development programs, potentially leading to the cessation of operations.
• The company is not in compliance with Nasdaq Listing Rule 5450(a)(1) due to its common stock trading below $1.00, and failure to regain compliance by December 24, 2025, could lead to delisting, negatively impacting share price and liquidity.
• Clinical trials may fail to meet their endpoints, or regulatory approval may not be obtained for product candidates, which are costly and time-consuming processes.
• The company has no products approved for commercial sale and has never been profitable, expecting to incur significant and increasing operating losses for the foreseeable future.
• Future capital requirements are difficult to forecast and depend on many factors, including the timing and success of clinical trials, regulatory submissions, and commercialization activities.
• Raising additional capital through equity securities will dilute existing stockholders, and debt financing may involve restrictive covenants.
• Foreign currency exchange rate fluctuations, particularly between the U.S. dollar and the Euro/Australian dollar, could adversely affect financial results, as a significant portion of operations are in Germany and Australia.
• The industry is characterized by frequent claims and litigation, including securities litigation, patent disputes, and product liability claims, which could involve the company in the future.

Future Outlook

Immunic expects to incur significant and increasing operating losses for the foreseeable future as it continues the development of its product candidates and expands its personnel. Top-line data for the Phase 3 ENSURE trials of vidofludimus calcium in RMS is anticipated by the end of 2026. The company plans to prepare for further clinical testing of IMU-856, contingent on securing additional financing, licensing, or partnering. Strategic initiatives include exploring additional indications for existing candidates, generating new molecules, facilitating pre-commercial readiness, and evaluating strategic collaborations or a potential spin-off for certain assets. The company's ability to fund these operations for the next twelve months is uncertain without additional capital.

Management Comments

• "We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to advance our pipeline of product candidates."
• "We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to the timing of development programs."
• "With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these consolidated financial statements included in this Quarterly Report without raising additional capital and such actions are not solely within the control of the Company."
• "If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company’s ability to continue as a going concern."
• "Although we currently believe that this goal [top-line data for ENSURE by end of 2026] is achievable, it is dependent on numerous factors, most of which are not under our direct control and can be difficult to predict."
• "We believe that, since 24wCDW is an accepted regulatory endpoint to demonstrate clinical benefit in PMS, this evidence of clinical activity merits further investigation and de-risks a potential Phase 3 program."
• "We are currently considering whether to apply for initial listing on the Nasdaq Capital Market to seek an additional 180-day compliance period to regain compliance with the minimum $1.00 closing bid price requirement."

Industry Context

Immunic operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel oral therapies for neurologic and gastrointestinal diseases. The positive clinical data for vidofludimus calcium in MS, particularly its neuroprotective potential and favorable safety profile, positions it as a potentially unique treatment option in a market with significant unmet needs. The exploration of IMU-856 for weight management also taps into a rapidly growing and lucrative market. However, the company's significant accumulated deficit, ongoing operating losses, and explicit 'going concern' warning highlight the inherent financial risks and challenges faced by many development-stage biotech companies that rely heavily on external funding to advance their pipelines. The Nasdaq delisting notice further underscores the precarious position, as maintaining public listing is crucial for capital access and investor confidence in this industry.

Comparison to Industry Standards

• Immunic's accumulated deficit of $589.3 million and consistent operating losses since inception are common for early to late-stage biotechnology companies that have no commercialized products and are heavily invested in R&D.
• The cash burn rate, with $66.5 million used in operating activities over nine months, is typical for a company with multiple drug candidates in Phase 2 and Phase 3 clinical trials, which are the most expensive stages of drug development.
• The failure of the conditional tranches of the January 2024 financing to close, totaling $160 million, is a significant setback, indicating a challenge in meeting market-based performance conditions, which can be a red flag for investors compared to peers who successfully secure such funding.
• The Nasdaq non-compliance notice for falling below the $1.00 minimum bid price is a serious concern, as delisting can severely impact liquidity and investor perception, a situation many smaller biotech firms face when clinical milestones or financing efforts fall short.
• The positive Phase 2 CALLIPER data for vidofludimus calcium in PMS, showing reductions in disability progression and brain volume loss, is a strong clinical signal that, if replicated in Phase 3, could position the drug favorably against existing MS therapies, many of which primarily target inflammation rather than neuroprotection.
• The long-term safety and tolerability profile of vidofludimus calcium in RRMS, with low discontinuation rates over 5.5 years, is a competitive advantage in chronic disease management, where patient adherence and safety are critical factors for market adoption.
• The exploration of IMU-856 for weight management, based on GLP-1 increase and preclinical data, places Immunic in a highly competitive but potentially high-reward therapeutic area, similar to the recent successes seen with GLP-1 agonists from companies like Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro).

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition, or cash flows.
• The industry is characterized by frequent claims and litigation, including securities litigation, patent and intellectual property rights claims, and product liability claims, suggesting potential future involvement in legal proceedings.

Related Party Transactions

• Addendum Number 6, dated August 29, 2024, to the Executive Chairman Agreement with Duane Nash, MD, JD, MBA, extending his employment as Executive Chairman of the Board to December 31, 2025, and increasing his monthly base salary in 2025 to $33,986 from $32,368.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent and potential future equity offerings, including warrants. The 'going concern' warning and Nasdaq delisting risk pose substantial threats to investment value and liquidity. The failure of the January 2024 financing tranches to close represents a missed opportunity for non-dilutive funding.
• **Employees**: Benefit from stock-based compensation plans, including stock options and newly authorized Stock Appreciation Rights (SARs). The Corporate Transaction Option Acceleration Plan provides a potential benefit in the event of a change of control, aiming to retain key personnel.
• **Customers (future patients)**: Stand to benefit from the continued development of novel oral therapies for serious chronic inflammatory and autoimmune diseases, particularly vidofludimus calcium for MS and IMU-856 for GI diseases and potentially weight management, if regulatory approvals are achieved.
• **Creditors**: May face increased risk due to the company's 'going concern' warning and reliance on future capital raises to sustain operations.
• **Suppliers/CROs**: Continued engagement for research and development activities, but the company's liquidity challenges could impact future contracts or payment terms if additional capital is not secured.

Next Steps

• Continue to fund the ongoing clinical development of product candidates, including the Phase 3 ENSURE trials for vidofludimus calcium in RMS.
• Complete the analysis of the full data set of the Phase 2 CALLIPER clinical trial and discuss results with healthcare authorities to determine next steps for vidofludimus calcium in PMS.
• Prepare for additional clinical testing of the IMU-856 development program, contingent on financing, licensing, or partnering.
• Continue preclinical research to complement existing clinical activities, explore additional indications, and generate new molecules.
• Facilitate readiness for potential commercial launch of product candidates, if regulatory approvals are received, through targeted pre-commercial activities.
• Evaluate potential strategic collaborations for each product candidate to complement R&D capabilities and facilitate commercialization.
• Actively monitor the common stock's closing bid price and evaluate options to regain compliance with Nasdaq's minimum bid price requirement, including potentially applying for initial listing on the Nasdaq Capital Market.
• Seek stockholder approval to increase the number of shares available under the 2019 Omnibus Equity Incentive Plan to support settlement of Stock Appreciation Rights (SARs) with shares.

Key Dates

Recommendation

The company explicitly states a 'substantial doubt about its ability to continue as a going concern' due to inadequate liquidity for the next twelve months without additional capital. This is a critical red flag. Furthermore, the failure of the second and third tranches of the January 2024 financing, which would have provided $160 million, to close is a significant negative event, indicating a failure to meet crucial financial or market conditions. The Nasdaq non-compliance notice and the risk of delisting further compound the negative outlook, severely impacting market confidence and liquidity. While there are positive clinical updates, the overwhelming financial instability and existential threat to the company's operations make it a strong sell for investors.

Keywords

Biotechnology, Multiple Sclerosis, MS, Relapsing Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Celiac Disease, Inflammatory Bowel Disease, IBD, Weight Management, IMU-838, vidofludimus calcium, IMU-856, IMU-381, Clinical Trials, Phase 3, Phase 2, Drug Development, Biopharma, SEC Filing, 10-Q, Nasdaq Delisting, Going Concern, Capital Raise, Warrants, Biomarkers, Neuroprotective, Anti-inflammatory, SIRT6, GLP-1